Seeking Alpha

Jim Van Meerten's  Instablog

Jim Van Meerten
Send Message
Jim Van Meerten is an advisor to Marketocracy Capital Management and writes on financial subjects here and on Barchart Portfolio Blogs. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and attended... More
My company:
Marketocracy Capital Management
My blog:
Barchart Portfolio Blogs
  • Cancer research and treatment has interests 0 comments
    Jul 21, 2010 11:32 AM | about stocks: GILD
    On Barchart Portfolio Blogs I bring to your attention stocks you might want to consider for your portfolio.

    YM BioSciences Inc.(YMI) is being added to the Barchart Van Meerten Speculative portfolio. The company engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment of nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain.

    Recent price appreciation of 16.24% last month plus hitting 11 new highs in the last 20 trading sessions is a reason to take notice. Barchart Trend Spotter (tm) signals a buy and the stock is trading above its 20, 50 and 100 day moving averages. The stock trades at 1.36 with a 50 day moving average of 1.28.

    Wall Street brokerages have 2 buy recommendations for their clients based on a prediction of a 190.70% sales increase next year. Earnings per share are estimated to increase 13.00% this year and 25.00% next year. Pretty aggressive estimates.

    The investing community has noticed this stock and the Motley Fool CAPS members think the stock will beat the market by a vote of 91 to 1.

    The reasons I'm adding YM Biosciences (YMI) to the Barchart Van Meerten Speculative portfolio:

    • 11 new highs in the last 20 sessions
    • Barchart Trend Spotter (tm) buy signal
    • Wall Street recommendations to buy based on increased sales and earnings
    • Positive investor sentiment

    Jim Van Meerten is an investor who writes on investing here and on Barchart Portfolio Blogs. Please leave a comment below or email JimVanMeerten@gmail.com.

     


    Disclosure: No psoitions in YMI at the time of publication
    Themes: Biotech Stocks: GILD
Back To Jim Van Meerten's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • Argan - Bartchart's Chart Of The Day $AGX http://seekingalpha.com/p/1tfdh
    about 13 hours ago
  • $GPRE - 100% Barchart technical buy signals - 10 new highs and up 12.97% for the month - Relative Strength Index 77.16%
    about 14 hours ago
  • $GTAT - 40% Barchart technical sell signal - 8 new highs but down .12% for the month - Relative Strength Index 40.10%
    about 14 hours ago
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.